| Active substance | Gemtuzumab Ozogamicin |
| Holder | PFIZER s.a./n.v. |
| Status | Closed |
| Indication | Treatment of patients with a diagnosis of CD33-positive relapsed or refractory acute myeloid leukemia (AML) or CD33-positive relapsed or refractory acute promyelocytic leukemia (APL). |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 29/05/2019 |
Mylotarg®
Last updated on 03/04/2024